Sormani MP, Häring DA, Kropshofer H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, 277.
D2 CAR T-cellen bij gerecidiveerd of refractair hoogrisico neuroblastoom
jun 2023 | Neuro-oncologie